Evercrisp Biosciences, founded by world-renowned scientists who bring expertise and proprietary technology to the company, is currently operating in stealth mode with a substantial Series A commitment from Apple Tree Partners (ATP) to take the company from discovery to proof of concept. Evercrisp is initially focused on high-confidence, genetically validated but "difficult to drug" targets in areas of high unmet need where genome editing can make a significant difference.